文献速递银屑病与炎症性皮肤病湿疹皮炎与荨麻疹

集中药房干预对皮肤科预先授权流程及患者结局的影响

Examining the prior authorization process, patient outcomes, and the impact of a pharmacy intervention: A single-center review.
PubMed 文献 · J Am Acad Dermatol · 2019-05-16

单中心回顾性综述评估皮肤科药物预先授权(PA)负担及集中药房干预的效果:PA占全部处方的8.1%,干预后PA提交时间与决定时间均缩短、批准率提高,但PA总数未减少;PA获批患者疾病改善的可能性高于被拒者。

要点

  • 生物制剂(55.2%)与仅品牌药(42.8%)的PA要求率更高。
  • 集中药房干预缩短PA提交与决定时间并提高批准率,但未减少PA总量。
  • PA获批者疾病改善率71.1%,高于被拒者的58.0%。

核心结论

  • 现行PA流程可能导致诊疗延迟并对患者产生负面影响。
  • 集中药房干预是有效措施,但不能消除PA的总体负担。
  • PA获批患者比被拒患者更可能获得疾病改善。

研究设计与样本

  • 单中心回顾性综述,比较药房干预实施前后提交的PA。
  • 数据来自单一学术机构,未评估患者用药依从性。

主要发现

  • PA占全部处方的8.1%。
  • PA最常提交于外用糖皮质激素、外用抗生素与抗真菌药及外用维A酸类。
  • 最常见适应证包括痤疮、银屑病和皮炎。
  • 生物制剂(55.2%)和仅品牌药(42.8%)的PA要求率更高。

关键数值与推荐

  • 药房干预后PA提交时间由4天缩短至1天(P < .001)。
  • PA决定时间由6天缩短至1天(P < .001)。
  • PA批准率由63.9%提高至80.6%(P < .001)。
  • PA获批者疾病改善率71.1%,被拒者58.0%(P = .013)。

临床怎么用

  • 皮肤科应关注高PA负担药物(生物制剂、仅品牌药)的授权流程管理。
  • 可考虑集中药房干预以加快PA提交与决定并提高批准率。
  • 需认识到药房干预不能减少PA总量,整体负担仍需其他措施。

局限性

  • 数据来自单一学术机构。
  • 未评估患者用药依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dermatology experiences a disproportionately high burden of prior authorizations (PAs). OBJECTIVE: To examine the effect of a centralized pharmacy intervention on the PA process and the impact of PAs on patient outcomes. METHODS: A retrospective review of PAs submitted for medications before and after implementation of pharmacy intervention was conducted. RESULTS: PA was required for 8.1% of all prescriptions. PAs were most frequently submitted for topical steroids, topical antibiotics and antifungals, and topical retinoids. Most common indications included acne, psoriasis, and dermatitis. Biologic agents (55.2%) and brand-name only medications (42.8%) required PA at higher rates. Pharmacy intervention resulted in shorter time to PA submission (4 days vs 1 day, P < .001) and decision (6 days vs 1 day, P < .001) and higher approval rates (63.9% vs 80.6%, P < .001) but did not decrease the total number of PAs. Patients with approved PAs had higher likelihood of disease improvement vs those with denied PAs (71.1% vs 58.0%, P = .013). LIMITATIONS: Data were collected from a single academic institution. Patient medication compliance was not assessed. CONCLUSIONS: The current PA process may result in delays in care and a negative impact on patients. A centralized pharmacy intervention is an effective measure but does not eliminate the overall burden of PAs.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Popatia S, Flood KS, Golbari NM, et al. Examining the prior authorization process, patient outcomes, and the impact of a pharmacy intervention: A single-center review. J Am Acad Dermatol. 2019. PMID: 31103568. doi:10.1016/j.jaad.2019.05.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。